The proteotoxic-stress response pathway, controlled by heat shock factor 1 (HSF1), supports both cancer progression and chemoresistance and is an attractive target for cancer treatment. As developing HSF1 inhibitors has proved to be very challenging, the identification and targeting of upstream regulators of HSF1 presents a more tractable alternative strategy.
Introduction
TNBC is a heterogeneous group of breast tumours defined by their lack of expression of estrogen (ER), progesterone (PR) and Her2 receptors, accounting for about 15-20% of all breast cancer cases 1 . TNBC tend to be diagnosed with higher grade cancer, have a greater rate of recurrence and metastases, and do not respond to ER-or HER2-targeted therapies, resulting in limited therapeutic options 2 . New strategies coupled with patient stratification approaches to predict likely responders to new emerging treatments are urgently required to enhance the therapeutic options in TNBC.
Breast cancer cells, as most cancer cells, are exposed to sustained proteotoxic stress as a result of severe aneuploidy and high mutation load, which increases the amount of toxic, misfolded proteins in the cell 3, 4 . This proteotoxic stress is countered by the proteotoxic stressresponse pathway, which promotes the correct folding of proteins via the heat shock factor 1 (HSF1) pathway (also known as the heat shock response). HSF1 therefore helps cancer cells to survive, supporting oncogenesis. This has been demonstrated by the reduced susceptibility of Hsf1-knockout mice to tumour formation driven either by Ras or p53 mutations or by chemical carcinogens 5 . At basal conditions, HSF1 is maintained mainly in the cytoplasm and upon proteotoxic stress, HSF1 is activated and translocates to the nucleus 6 . HSF1 activity and stability are tightly controlled by multiple post-translational modifications 7 . Among these, phosphorylation of serine 320 and serine 326 are associated to enhanced transcriptional activity, stability and nuclear accumulation of HSF1 [8] [9] [10] . Although the sequence of modification events leading to HSF1 activation or the interplay among the different phosphorylation events are unclear, the predominant view is that phosphorylation on S326 is critical and dominant over any inhibitory phosphorylation events, and thus HSF1 phosphorylated on S326 is a hallmark for HSF1 activation 11 . Once in the nucleus, HSF1
activates a transcriptional program including a number of heat shock proteins (HSPs), which function as molecular chaperones, facilitating the folding, transportation, ubiquitination, and proteasomal degradation of proteins 12, 13 , protecting cells against proteotoxic stress and apoptosis 14 . Of the HSPs, HSP70, is one of the best-characterised HSF1 targets, and is expressed at high levels in a variety of cancers, correlating with growth, survival, invasion and resistance to therapy 15 . For breast cancer in particular, high levels of HSF1 correlate with poor prognosis 16 and HSF1 depletion strongly reduces proliferation and viability of breast cancer cells, without affecting normal breast epithelial cells 5 .
Although there is no direct evidence linking dual-specificity tyrosine-phosphorylationregulated kinase 2 (DYRK2) to the HSF1 pathway in human cells, the yeast homolog of DYRK kinases, YAK1, phosphorylates and activates HSF1 17 . Thus, we hypothesized that DYRK2, by regulating the HSF1 pathway, could have a role in controlling proteotoxic stress responses and contributing to TNBC tumour progression.
Herein we found that DYRK2 phosphorylates and activates HSF1, promoting resistance to proteotoxic stress in TNBC cells, and tumour growth in TNBC xenograft models. We further report that the DYRK2-HSF1 link is also relevant in clinical TNBC samples. DYRK2 protein levels correlates with nuclear levels of HSF1, and associates with poor cancer-specific patient survival and high tumour recurrence. Together our data reveal DYRK2 as a kinase that promotes cancer cell survival by activating the HSF1 pathway, and support a tumour promoting role for DYRK2 in TNBC.
Results

1-DYRK2 phosphorylates HSF1
To test whether DYRK2 phosphorylates HSF1, we overexpressed DYRK2 and, by use of phosphospecific antibodies, we observed that the levels of endogenous HSF1 phosphorylated at S326 and S320 were increased (Fig. 1A) ; for this effect, the kinase activity of DYRK2 was required, as a kinase-dead version of DYRK2 (DYRK2-KD) did not induce HSF1
phosphorylation. To further test the role of DYRK2 kinase activity on HSF1 phosphorylation, we mutated the gatekeeper residue within DYRK2, creating an analogue-sensitive DYRK2 form (DYRK2-AS) that is selectively sensitive to PP1 inhibitors 18 . Using the DYRK2-AS form together with three different PP1 inhibitors, we observed that specific inhibition of DYRK2 activity, dose-dependently reduced the DYRK2-mediated phosphorylation of endogenous HSF1 (Fig. 1B) . Additionally, harmine, a well characterised pan-specific DYRK inhibitor 19 , was also able to reduce the phosphorylation of endogenous HSF1 mediated by DYRK2 overexpression (Fig. S1A ).
To address if HSF1 is a direct substrate for DYRK2, we performed an in vitro kinase assay using recombinant His-HSF1 and GST-DYRK2. In close agreement with the cell culture experiments, we found that DYRK2 phosphorylates His-HSF1 at S326 and S320 in vitro (Fig. 1C) .
Furthermore, incubation of recombinant GST-DYRK2-AS with a PP1 inhibitor inhibited the phosphorylation of His-HSF1 on both S326 and S320 (Fig. S1B ). Mass spectrometry analysis of a sample taken at an early time point (5 minutes) from the in vitro reaction showed that HSF1
was further phosphorylated at S307, T323 and S363 (Fig. S1C) . Unfortunately, only antibodies against S307 were commercially available, and in our analysis, endogenous HSF1 was not phosphorylated at this site upon DYRK2 overexpression (not shown). We therefore focused on S320, S326, T323 and S363 in our subsequent studies.
Once we established that DYRK2 can phosphorylate HSF1 in cells and in vitro, we tested whether DYRK2 plays a role in HSF1 phosphorylation in response to proteotoxic stress in TNBC cell lines, using MDA-MB-231 and MDA-MB-468 as models. Using heat shock as a proteotoxic stress inducer, we showed that DYRK2 depletion leads to a reduction of HSF1 phosphorylation in response to heat shock (Fig. 1D ). To test if this effect was specific for DYRK2, we silenced individually two other members of the DYRK family, DYRK1A and DYRK1B. We found that in our TNBC cell models, DYRK2 is the main DYRK member involved in HSF1 phosphorylation (Fig. 1E) , although other members of the family can also modulate HSF1 to a lesser extent. This is also the case in other cancer cell lines (Fig. S1D ). In agreement with the role of DYRKs in heat shock-mediated HSF1 phosphorylation, incubation with harmine dramatically impaired HSF1 phosphorylation in response to heat shock in TNBC cells (Fig. 1F) .
Interestingly, in addition to reducing HSF1 phosphorylation, DYRK2 knockdown appeared to reduce the levels of HSF1 under heat shock conditions (Fig. 1D, 1E , and Fig. S1D ), which could be a cause or a consequence of the lower HSF1 phosphorylation levels. However, acute (1 hour) harmine-mediated DYRK inhibition reduced HSF1 phosphorylation without affecting HSF1 levels ( Fig. 1F ) which, based on the HSF1 relatively long half-life (>6 hours) 10, 20 , suggests that reduction of HSF1 phosphorylation might precede or is uncoupled to HSF1 destabilisation.
2-DYRK2 interacts with HSF1 via two domains
Our results provide evidence to support a functional interaction between DYRK2 and HSF1. In order to test whether DYRK2 and HSF1 physically interact in cells, we performed coimmunoprecipitation. The interaction between the two proteins, which was not easily detectable at basal conditions, was increased upon exposure to proteotoxic stress ( Fig. 2A and 2E). This weak interaction might reflect a transient binding between DYRK2 and HSF1, which is a common occurrence for kinases and their substrates. In order to map the interaction site(s), we used an in vitro interaction peptide array. By incubating recombinant GST-HSF1 with a membrane containing an array of overlapping peptides covering the entire DYRK2 protein, we identified two potential binding regions (Fig. 2B ) within conserved aminoacid sequences (Fig. S2A ). Binding region 1 (BR1) with sequence DDQGSYV, is located in a surface-exposed loop, and binding region 2 (BR2) with sequence TDA, falls within the unstructured C-terminus of DYRK2 (Fig. S2B) . Although protein loops are not involved in regulating kinase activity, they often play a crucial role in mediating protein-protein interactions 21 . In order to validate the functional relevance of these two regions, we created DYRK2 constructs harbouring mutations either in BR1 or BR2, or in both simultaneously.
Based on our results, BR1 appeared to be more important for the ability of DYRK2 to phosphorylate HSF1 (Fig. 2C) . Furthermore, when both DYRK2 binding regions were mutated, HSF1 phosphorylation was strongly reduced in both S320 and S326, but notably, the ability of DYRK2 to phosphorylate SIAH2 22 , another known substrate, remained intact (Fig. 2D ). This observation suggests that these two regions are not important for general DYRK2 kinase activity, but rather for its specific interaction with HSF1. As expected, the DYRK2 BR1/BR2 mutant (YV/AR-T/A) did not interact with HSF1 (Fig. 2E ).
3-DYRK2 promotes HSF1 nuclear stability
As nuclear HSF1 is the active form of HSF1, we asked whether DYRK2 was affecting HSF1 nuclear levels. We tested in TNBC cells the role of DYRK2 on the nuclear levels of HSF1 at basal and after heat shock conditions by employing stable CRISPR-mediated knockout as well as siRNA-mediated knockdown. Both DYRK2 depletion strategies reduced HSF1 nuclear levels in basal conditions and after heat shock, as well as the levels of nuclear phospho-HSF1 in TNBC cells ( Fig. 3A and Fig. S3A, S3B ). This was also the case for other cancer cell lines ( Fig. S3C and   S3D ). We used two independent gRNAs to knockout DYRK2 in the different TNBC cell lines, obtaining in both cases the same reduction in levels of nuclear HSF1 as with siDYRK2, suggesting a specific effect. Nevertheless, to further confirm the on-target effect of DYRK2 on HSF1 nuclear levels, we reconstituted DYRK2-KO cells with DYRK2, showing that the levels of nuclear HSF1 and phospho-HSF1 in DYRK2-KO cells were rescued (Fig. 3B) . Moreover, DYRK2
overexpression resulted in increased HSF1 nuclear levels and phosphorylation (Fig. S3E ).
In agreement with our previous results, acute harmine-mediated DYRK inhibition led to reduction in nuclear HSF1 phosphorylation without affecting nuclear HSF1 levels (Fig. 3C) . To assess the effect of DYRK2 on HSF1 stability, we compared the HSF1 nuclear and cytosolic levels upon cycloheximide treatment in control and DYRK2 knocked-down TNBC cells. In cycloheximide chase experiments, DYRK2 depletion reduced the levels of nuclear but not cytosolic HSF1, suggesting that DYRK2 controls HSF1 nuclear stability (Fig. 3D ).
The positive effect of DYRK2 on HSF1 stability could be either dependent or independent of DYRK2-mediated HSF1 phosphorylation. We reasoned that as phosphorylation on S326 and on S320 are known to promote HSF1 stability and nuclear accumulation respectively 8, 10 , those two sites were most likely responsible for the positive effect of DYRK2 on HSF1 nuclear stability. Unexpectedly, our results showed that mutation of S326 and/or S320 were not sufficient to completely abolish the effect of DYRK2 on HSF1 stability (Fig. S3F) . Nevertheless, additional mutation of the other two identified sites (T323 and S363) significantly reduced the effect of DYRK2 on HSF1 stability (Fig. 3E ). These results demonstrate the relevance of the combined phosphorylation on HSF1 for the effect of DYRK2 on HSF1 stability, although we cannot completely rule out the participation of additional mechanisms unrelated to HSF1 phosphorylation.
4-DYRK2 affects the expression levels of the HSF1 target gene HSP70
Based on its positive effect on the levels of nuclear phosphorylated HSF1, we hypothesised that DYRK2 could be promoting HSF1 transcriptional activity. To test this hypothesis, we compared the levels of the prototypic HSF1 target gene, heat shock protein 70 (HSP70), in TNBC cells with and without DYRK2. DYRK2 knockout reduced significantly the induction of HSP70 mRNA levels in response to heat shock ( Fig. 4A and 4B ) and in response to bortezomib, another inducer of proteotoxic stress (Fig. S4A) . Similarly, HSF1 knockout strongly affected the levels of HSP70, whereas HSF1/DYRK2 double knockout did not reduce the HSP70 mRNA levels any further, confirming that the effect of DYRK2 on the expression of HSP70 is mediated by HSF1 (Fig. 4A) . Importantly the reduction on HSP70 levels observed in DYRK2-KO cells was recovered by reconstituting them with DYRK2 (Fig. 4C ). In addition, harmine reduced the HSP70 mRNA levels in a DYRK2-dependent manner in TNBC as well as in other cancer cell lines (Fig. S4B) .
5-DYRK2 reduces sensitivity to proteotoxic stress via HSF1
To assess the functional significance of the reduced HSF1 activity in DYRK2-impaired TNBC cells, we tested the effect of DYRK2 depletion on the sensitivity of these cells to proteotoxic stress. In agreement with our data on the importance of DYRK2 for HSF1 function and with the well-characterised protective role of HSF1 against proteotoxicity, DYRK2 depletion (both by siRNA and CRISPR-mediated knockout) sensitised TNBC cells to heat shock, as measured by levels of PARP cleavage, a marker of apoptosis ( Fig 5A, 5B and Fig. S5A ). The same result was observed in other cancer cell lines (Fig. S5B ).
As expected, HSF1-deficient cells were more sensitive to heat shock than wild-type cells.
Importantly, the effect of DYRK2 depletion on the enhanced sensitivity to proteotoxic stress on wild-type cells was largely abolished in TNBC HSF1-KO cells (Fig. 5C ), confirming the involvement of HSF1. In agreement, harmine sensitised TNBC cells to heat shock in a HSF1-dependent manner (Fig. S5C) . Together, these results strongly suggest that DYRK2 has a role in the HSF1-mediated resistance to proteotoxic stress. figure S6A ). When samples were divided into high and low expression groups for either HSF1 or DYRK2 (H-score: < or >145 for cytoplasmic and nuclear DYRK2; < or > 156 for cytoplasmic HSF1; and < or > 100 for nuclear HSF1), nuclear HSF1 positively correlated with nuclear DYRK2, but not cytoplasmic DYRK2 ( Fig. 6A and S6B ). Interestingly, when cytoplasmic HSF1 was analysed, no association was observed with DYRK2. Our data further support the conclusion that DYRK2 positively regulates HSF1 nuclear levels in tissue from TNBC patients.
Based on this novel correlation between DYRK2 and HSF1 in TNBC human samples and on the known association of nuclear HSF1 with poor prognosis, we hypothesised that high levels of nuclear DYRK2 would associate with poor prognosis in TNBC. To test this hypothesis, we utilised a cohort of 750 breast cancer samples that had available a previously constructed tissue microarray, including 148 TNBC (TMA information in Fig. S6C ). Human tumour samples were stratified on the basis of high or low H-score (H-score: low<145 WHUs and high>145
WHUs). DYRK2 protein levels were assessed in 3 individuate TMA cores and mean WHU employed for analysis (representative figures with high and low DYRK2 levels in Fig. S6D ). In the full cohort, DYRK2 levels did not associate with survival (Fig. S6E) . However, in TNBC samples, high nuclear DYRK2 levels significantly associated with reduced cancer-specific survival ( Fig. 6B) but not with overall survival (Fig. S6F) . Notably, the strength of this association was highest in the TNBC subgroup of patients with ER, PR, HER2, and AR negative disease (Fig. 6C) . In TN-AR negative samples, nuclear DYRK2 was observed as an independent factor in Cox Regression multivariate analysis when combined with other clinical parameters (Fig. S6G) . Moreover, high DYRK2 levels were associated with shorter time to recurrence in both TNBC and TN-AR negative breast cancer (Fig. S6H) .
These results establish DYRK2 protein levels as potential prognostic factor and promissing novel therapeutic target in TNBC, especially in the TN/AR-negative subgroup of patients, for whom there is no targeted therapy available. Interestingly, several of the commonly used TNBC cell models (including the two cell lines used in this study, MDA-MB-231 and MDA-MB-468) are also AR negative 23 , and thus there is full agreement between our cell culture and tissue analysis data. 
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Discussion
The HSF1 pathway represents an attractive therapeutic target as it plays roles in both cancer progression and chemoresistance 5, 11, 16, 24, 25 . However, developing specific HSF1 inhibitors has proven to be challenging, and thus, an alternative approach is to understand and to target HSF1 upstream regulatory pathways. In this study, we shed light on the regulation of the HSF1 pathway by the kinase DYRK2. Other kinases have been shown to activate HSF1 by phosphorylating the same residues as DYRK2 (i.e. MEK1, mTOR and p38 MAPK phosphorylate S326 10, 26, 27 and PKA phosphorylates S320 8 ), and thus we did not expect DYRK2 depletion to completely abolish HSF1 phosphorylation. Remarkably, DYRK2 depletion significantly reduced HSF1 phosphorylation and its nuclear levels, and was sufficient to impair HSF1 response and promote TNBC apoptosis. This finding suggests that either these other kinases are not relevant in TNBC cells, or they cannot completely compensate for the absence of DYRK2. The latter could be either because DYRK2 is necessary for a full HSF1 activation, or because the combined/sequential effect of multiple kinases is necessary, and thus elimination of any of the individual kinases involved would impair HSF1 response. Further studies are necessary to clarify this point, but nevertheless, our results indicate that DYRK2 is a major kinase controlling HSF1 activation in TNBC. Also, it is important to point out that DYRK2 is, to date, the only known kinase that phosphorylates HSF1 on both S320 and S326, which are associated with its activation. Interestingly, DYRK2 can phosphorylate HSF1 on at least four sites in vitro, and the mutagenesis studies show that only when all four sites are mutated, the effect of DYRK2 on HSF1 stability is lost, suggesting that those sites play a role in vivo. Although how these sites control HSF1 stability is not known, the fact that DYRK2 might phosphorylate sites associated with both positive (S326, S320) and negative (S363) regulation of HSF1 might appear counter-intuitive. We propose that this conundrum could be explained by the current view that phosphorylation of S326 dominates over any other phosphorylation events. Thus, during heat shock, HSF1 undergoes both activating and inhibitory phosphorylation events, but as long as S326 is phosphorylated, the overall effect is HSF1 activation. Once S326 is dephosphorylated, the inhibitory phosphorylation events ensure that the HSF1 response is transient and does not persist.
We have shown that DYRK2 activates the pro-survival HSF1 pathway providing a support mechanism and a survival advantage to cancer cells. Importantly, this new link between DYRK2 and HSF1 appears to be relevant in TNBC patients as DYRK2 levels correlate positively with HSF1 nuclear levels, and negatively associates with cancer specific survival and time to recurrence, supporting a pro-tumoural role for DYRK2 in TNBC. Furthermore, we showed that DYRK2 predominantly affects nuclear HSF1, which is consistent with the observed increase in nuclear levels of DYRK2 in response to proteotoxic stress (Fig. 3A , 3B, S3A, S3B, S3C). This observation in cell lines, combined with the positive correlation between levels of nuclear DYRK2, nuclear HSF1 and association with patient prognosis observed in tumour samples suggest that the nuclear pool of DYRK2 is responsible for its HSF1-dependent tumour promoter role in TNBC.
Our results suggest that DYRK2 may be both a prognostic biomarker and a therapeutic target, which will be especially relevant in TN-AR negative (or quadruple negative) breast cancer patients, for whom there is no targeted therapy available. The development of new specific DYRK2 inhibitors and their validation in vivo (i.e. using xenograft and genetic models) is needed to further substantiate this hypothesis. In this context, it is encouraging to see in our study the dramatic inhibitory effect of the DYRK inhibitor harmine on HSF1 activation and 
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The authors declare no competing interests. was measured. ****p<0.0001, ***p<0.001, *p<0.05 (compared to scrambled control, twoway ANOVA, mean ± SD from n=8 mice each).
Material and Methods
Cell culture
All cell lines used in the study have been validated by STR profiling and were routinely tested for mycoplasma. All cell lines were grown in DMEM containing 10% FBS at 37°C and 5% CO2.
Antibodies, plasmids and reagents
Antibodies recognizing Flag (M2) were obtained from Sigma-Aldrich ( Expression vectors for DYRK2-GFP, DYRK2-KD-GFP, DYRK2-Flag and SIAH2-RM-HA were a gift from Marco A. Calzado (University of Cordoba, Spain); HSF1-GFP have been already described 27 . All gRNAS were cloned into pLentiCRISPr-V2, which was a gift from Feng Zhang (Addgene plasmid # 52961). Point mutants were produced by conventional point mutagenesis. The DYRK2-analog sensitive was obtained by mutating the gatekeeper residue F228 to Alanine. His-HSF1 has already been described 27 and GST-DYRK2 was obtained from the MRC Protein Phosphorylation and Ubiquitination Unit (School of Life Science, University of Dundee, UK). GFP-DYRK2 was cloned into the lentiviral 290-puro plasmid 31 obtaining a puro resistant construct that was used for reconstitution experiments.
The siRNAs used against DYRK2 were the SMART pool: ON-Target Plus from Dharmacon (CO, USA). The shRNAs used to target DYRK2 (shDYRK2-1 gggtagaagcggtattaaa and shDYRK2-2 ggagaaaacgtcagtgaaa) were expressed from the pLL3.7 vector Bortezomib was obtained from Santa Cruz Biotechnology. DMSO was obtained from SIGMAAldrich (MA, USA), Harmine was obtained from Tocris Bioscience (Bristol, UK) and the PP1 inhibitors were obtained from Cayman Chemicals (MI, USA).
Quantitative real time PCR (rt-qPCR)
RNA was extracted using RNeasy kit (QIAGEN). 500 ng of RNA per sample was reversetranscribed to cDNA using Omniscript RT kit (QIAGEN) supplemented with RNase inhibitor (QIAGEN) according to the manufacturer's instructions. Resulting cDNA was analysed using TaqMan Universal Master Mix II (Life technologies). Gene expression was determined using an Applied Biosystems 7300 Real-Time PCR system by the comparative ΔΔCT method. All experiments were performed at least in triplicates and data were normalized to the housekeeping gene β-actin. Probes were obtained from Applied Biosystems. When applicable, the differences between groups were determined by 2 way ANOVA. Analyses were performed using GraphPad Prism (GraphPad Software); a P value of <0.05 was considered significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Cell transfections
On the day prior to transfection, cells were plated to the required cell density (70-90% confluency). Lipofectamine 2000 and Lipofectamine RNAiMAX (Invitrogen) were used for plasmid DNA and siRNA respectively. The plasmid DNA/siRNA and lipofectamine were individually diluted in Optimem (Gibco) and incubated for 10 minutes at room temperature.
Diluted DNA/siRNA was added to the diluted Lipofectamine solution (1:1 ratio) and further incubated for 15 minutes. DNA-lipid complex was added to the cells and incubated overnight in a humidified incubator at 37°C and 5% CO2. The next morning, the medium was replaced with fresh medium and cells were incubated 36 hours more prior lysis.
Lentivirus production
293T cells were transfected using Lipofectamine 2000 (Invitrogen) with the empty vector (pLL3.7) or the lentiviral shDYRK2-1 or shDYRK2-2 together with the packaging vectors (psPAX2 and pMD2.G) and cultivated in OptiMEM medium (Invitrogen). The next day the cells were further grown in DMEM complete medium and one day later the lentivirus-containing supernatant was collected, filtered and used to transduce cells.
Cell lysis protocol and western blotting
Cells were washed and harvested in ice-cold phosphate-buffered saline (PBS) and lysed in either SDS buffer or RIPA buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.5 mM Na3VO4, 50 mM NaF, 2 μg/ml leupeptine, 2 μg/ml aprotinin, 0.05mM pefabloc]. Cells directly lysed in SDS were boiled for two minutes, sonicated and boiled again for another 5 minutes. Cells lysed in RIPA buffer were sonicated and lysates were cleared by centrifugation for 15 minutes at 4°C. Protein concentration was established using the BCA assay (Pierce). Supernatant was mixed with SDS sample buffer and boiled for 5 minutes. Equal amounts of protein were separated by SDS-PAGE, followed by semidry blotting to a polyvinylidene difluoride membrane (Thermo Scientific). After blocking of the membrane with 5% (w/v) TBST nonfat dry milk, primary antibodies were added.
Appropriate secondary antibodies coupled to horseradish peroxidase were detected by enhanced chemiluminescence using Clarity™ Western ECL Blotting Substrate (BIO-Rad).
Subcellular fractionation (nuclear/cytoplasmic separation)
Cells were washed and harvested with ice-cold PBS. Pelleted cells were resuspended in 400μl of low-salt buffer A (10mM Hepes/KOH pH7.9, 10mM KCL, 0.1mM EDTA, 0.1mM EGTA, 1mM β-Mercaptoethanol). After incubation for 10 minutes on ice, 10μl of 10% NP-40 was added and cells were lysed by gently vortexing. The homogenate was centrifuged for 10 seconds at 13,200 rpm in a microfuge. The supernatant representing the cytoplasmic fraction was collected and the pellet containing the cell nuclei was washed 4 additional times in buffer A, then resuspended in 100μl high-salt buffer B (20mM Hepes/KOH pH7.9, 400mM NaCL, 1mM
EDTA, 1mM EGTA, 1mM β-Mercaptoethanol). The lysates were sonicated and centrifuged at 4°C for 15 minutes at 13,200 rpm. The supernatant representing the nuclear fraction was collected. Protease and phosphatase inhibitors were freshly added to both buffers.
Immunoprecipitation
Cells were washed with PBS and lysed in IP buffer (50 mM Hepes pH 7.5, 50 mM NaCl, 1%
(v/v) Triton X-100, 2 mM EDTA, 10 mM sodium fluoride, 0.5 mM sodium orthovanadate, leupeptine (10 µg/ml), aprotinin (10 µg/ml), and 1 mM PMSF), followed by a sonication step.
The extract was centrifuged and the supernatant was transferred to a new tube. The immunoprecipitation was performed with 2 μg of precipitating antibodies together with 50 µl of Dynabeads™ Protein G. Tubes were rotated for 30 min on a spinning wheel at 4°C. The immunoprecipitates were washed 3x with PBS/0,01% Tween-20 and eluted by boiling in 1 x SDS sample buffer. Equal amounts of protein were separated by SDS-PAGE.
CRISPR-edited cell lines
The endogenous DYRK2 and/or HSF1 genes were knocked-out by transfecting cells with pLentiCRISPR-v2 (which codes for Cas9, and a puromycin cassette) containing gRNAs against the first exon of the short DYRK2 isoform or against the fourth exon of HSF1. For MDA-MB-231, HeLa and 293T DYRK2-KO cells the gRNA sequence used was GCTTGCCAGTGGTGCCAGAG and for MDA-MB-468 DYRK2-KO cells the target sequence was CGCTCACGGACAGATCCAGG.
Additionally, we also tested some of our results in MDA-MB-231 cells in which we almost completely remove the DYRK2 ORF by using two gRNAs (N-term sequence GCTTGCCAGTGGTGCCAGAG and C-term sequence GAAGCTGAGCTAGAAGGTGG). For HSF1-KO cells the gRNA sequence used was AAGTACTTCAAGCACAACAA. Control cells were transfected with the empty pLentiCRISPRV2 vector. After transfection, cells were exposed to 2 μg/ml of puromycin for two days followed by a medium exchange. Surviving cells were clonally selected (in the case of control cells were used as pool population) by serial dilution, and positive clones were identified by genomic analysis and western blot. At least two clones for each cell line were used for the experiments.
In vitro kinase assay
Bacterially expressed full length HSF1 His tagged was incubated with GST-DYRK2 in Kinase
Buffer (25 mM TRIS pH 7.5, 5 mM β-glycerophosphate, 10 mM MgCl2 and freshly added 2mM DTT, 0.1 mM Na3VO4, 1 mM ATP) for different periods of time (5-60 min) at 30 ⁰C. The reaction was inactivated by adding SDS loading buffer (50 mM Tris-HCl pH 6.8, 10%, SDS, 40%
glycerin, 15% β-mercaptoethanol, 0.1 % bromophenol blue) and samples were boiled at 95 ⁰C for 5 minutes and loaded in SDS-PAGE gels.
In vitro peptide binding
Overlapping dodecapeptides covering the entire DYRK2 protein were spotted in an automated process on cellulose membranes by using Fmoc-protection chemistry (Proteomics facility, CNB-CSIC, Spain). The membrane was blocked overnight in non-fat milk in TBS buffer and incubated for 6 h with 60 nmol of recombinant GST-HSF1 or GST proteins as a control.
After extensive washing, anti-GST antibody coupled to horseradish peroxidase was added for 1 hour. After washing, blots were revealed by enhanced chemiluminescence using Clarity™
Western ECL Blotting Substrate (BIO-Rad).
Mass Spectrometry
Purified His-HSF1 (1ug) was incubated with GST-DYRK2 (20 ng) in 20 uL buffer containing 25mM Tris-HCl (pH7.5), 5 mM MgCl2, and 1 mM ATP for 5 minutes. The mixtures were reduced, alkylated and digested with trypsin (1:100) prepared in 100mM TEAB buffer (pH 8.5).
The mixture was incubated at 37°C overnight before 8 uL of 10mM EDTA (in 0.1% TFA) was added. The peptide mixture was then subjected to nano-LC-MS/MS analysis according to a previous report 32 . Database search was carried out using Peaks 7.0 against UniProt-human ER antibody and Leica (Wetzlar, Germany) PR antibody. Her2 status were assessed as described 33 .
Tissue analysis
IHC was conducted in triplicate on tissue microarrays (TMAs). Prior to this, antibody specificity was confirmed using proficient and deficient cell lines (either knockdown or knockout cell lines) (Fig S6A) . TMA sections (2.5µm) were dewaxed by immersion in histoclear then rehydrated using a series of alcohols. 
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